{"filings":[{"id":102753,"accession_number":"0001493152-26-005555","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ENvue Medical amends CEO equity plan, appoints David Johnson as Chairman with 3.5% RSU grant","event_type":"leadership","confidence":"high","bullets":["Amendment changes CEO Doron Besser's equity grants from annual to quarterly, with prorated gross-up on termination without cause.","David Johnson appointed Chairman; receives $10k/month and RSUs representing 3.5% of fully diluted common stock.","Chairman's RSUs vest over 2 years with anti-dilution protection; agreement auto-renews annually unless terminated.","Besser's initial RSU grant remains 9% of fully diluted shares, subject to Israeli Tax Authority approval.","Both agreements effective February 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102752,"accession_number":"0001493152-26-004523","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"ENvue Medical removes Series H Preferred Floor Price in exchange for $2.5M investment","event_type":"other_material","confidence":"high","bullets":["Entered Amendment Agreement with Required Holders to file Certificate of Amendment removing Floor Price from Series H Convertible Preferred Stock.","In consideration, holders exercised $2,500,000 of Additional Investment Right from July 2025 purchase agreement.","Certificate of Amendment filed and effective January 30, 2026.","The amendment modifies conversion rights of Series H Preferred by eliminating the Floor Price.","Company receives $2.5M new capital from existing preferred holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118984,"accession_number":"0001493152-25-029482","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ENvue Medical amends 2024 Long Term Incentive Plan for Israeli tax compliance and name change","event_type":"other","confidence":"high","bullets":["Board approved amended and restated 2024 Long Term Incentive Plan on December 24, 2025.","Adds restricted stock units under Section 102 for Israeli tax compliance; other non-material updates.","Reflects company name change from NanoVibronix to ENvue Medical and prior stockholder-approved amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118983,"accession_number":"0001493152-25-029018","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NanoVibronix amends CEO contract with 9% equity grant; appoints interim CFO","event_type":"leadership","confidence":"high","bullets":["CEO Doron Besser new base salary $360K, bonus up to $180K; severance of 12 months' base salary on change-of-control termination.","Besser receives 180,000 RSUs (9% of outstanding common stock) plus annual grants to maintain 9% equity.","CFO Stephen Brown departed Dec. 18, 2025; Nicole Fernandez-McGovern appointed Interim CFO via consulting agreement with RCM Financial Consulting.","Fernandez-McGovern receives $300K annual salary; served as CFO of NLS Pharmaceutics and interim CFO of Hayden AI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118988,"accession_number":"0001493152-25-027380","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"NanoVibronix changes name to ENvue Medical, ticker to FEED effective Dec 12, 2025","event_type":"other_material","confidence":"high","bullets":["Effective Dec 12, 2025, NanoVibronix changed name to ENvue Medical, Inc. and ticker symbol from NAOV to FEED on Nasdaq.","CEO Doron Besser said rebranding reflects new strategic direction focused on ENvue feeding-tube placement system.","Company aims to scale hospital utilization and build enteral-feeding ecosystem via internal and external development.","No stockholder action required; CUSIP unchanged; existing shares unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118987,"accession_number":"0001493152-25-026247","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NanoVibronix board reconstituted; four directors retire, five new directors elected, LTIP share pool expanded","event_type":"other_material","confidence":"high","bullets":["Christopher Fashek, Thomas Mika, Martin Goldstein, Brian Murphy retired immediately before the 2025 Annual Meeting for personal reasons; no disagreement with Company.","Stockholders elected Doron Besser, David Johnson, Zeev Rotstein, Nino Pionati, Alison Geiger Burgett as directors for one-year terms.","First Amendment to 2024 Long-Term Incentive Plan approved; shares reserved increased by 1,200,000 to 1,205,454 shares.","Share issuance proposal under Nasdaq Rule 5635(d) approved, covering convertible preferred stock and warrants from July 2025 private placement.","Kost Forer Gabbay & Kasierer (EY) ratified as independent auditor for FY 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118986,"accession_number":"0001493152-25-024167","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"NanoVibronix to rebrand as ENvue Medical, focus on enteral-feeding navigation platform","event_type":"other_material","confidence":"high","bullets":["ENvue feeding-tube placement system identified as core growth platform; 38 hospitals already using it.","U.S. enteral-feeding devices market projected at ~$1.8B by 2030; ENvue is 510(k)-cleared for adults.","Company planning name change to ENvue Medical and new NASDAQ ticker symbol.","Exploring strategic alternatives (partnerships/divestitures) for legacy PainShield and UroShield technologies.","CEO Doron Besser (appointed June 2025) outlines multi-phase roadmap including pediatric, imaging, and vascular applications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118985,"accession_number":"0001493152-25-020214","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoVibronix announces four directors will not stand for reelection at 2025 annual meeting","event_type":"leadership","confidence":"high","bullets":["Christopher Fashek, Thomas Mika, Martin Goldstein, and Brian Murphy to retire from Board immediately prior to 2025 Annual Meeting.","Fashek served on Audit, Nominating, and Compensation Committees; Mika on Audit and Compensation; Goldstein on Nominating.","Departures are for personal reasons and do not result from any disagreement with the Company.","No replacements for the departing directors have been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135530,"accession_number":"0001493152-25-013881","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"NanoVibronix prices $2M registered direct offering of common stock and prefunded warrants at $7.01","event_type":"other_material","confidence":"high","bullets":["Offering of 74,114 common shares and prefunded warrants for 217,090 shares at $7.01 per share (or $7.009 per warrant).","Gross proceeds of ~$2.0M; net proceeds ~$1.8M after placement fees and expenses.","Proceeds to be used for working capital, repayment of debt and/or redemption of preferred stock.","Palladium Capital Group acted as exclusive placement agent; closing expected September 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135529,"accession_number":"0001641172-25-023995","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"NanoVibronix dismisses Zwick CPA, appoints E&Y as auditor; CFO Brown gets amended deal","event_type":"other_material","confidence":"high","bullets":["Dismissed Zwick CPA PLLC; new auditor is Kost Forer Gabbay & Kasierer (E&Y) for FY2025.","Zwick's reports included a going-concern explanatory paragraph; material weaknesses in internal controls identified.","CFO Stephen Brown entered amended employment agreement with $300K annual salary, effective Aug 11, 2025.","Severance of $180K if terminated without cause or resignation after 6-month anniversary, conditional on release and reaudited financials.","Audit committee approved changes; no disagreements with Zwick on accounting principles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135528,"accession_number":"0001641172-25-022751","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"NanoVibronix effects 1-for-10 reverse stock split effective Aug 11, 2025","event_type":"other_material","confidence":"high","bullets":["Reverse stock split reduces outstanding shares from 7,968,868 to ~796,887.","Effective 4:05 p.m. ET on Aug 11, 2025; split-adjusted trading begins Aug 12, 2025.","No fractional shares issued; any fractional shares rounded up to whole number.","Adjustments made to equity awards, warrants, and convertible securities proportionally.","New CUSIP 63008J884; trading symbol remains NAOV on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135527,"accession_number":"0001641172-25-021544","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoVibronix appoints Rita Silberberg as EVP Finance, CAO and Corporate Secretary","event_type":"leadership","confidence":"high","bullets":["Appointment effective July 24, 2025; Silberberg also named Corporate Secretary same day.","Silberberg brings 15+ years experience; prior CFO at Gravity Creative Space and Director at Ernst & Young.","Employment agreement provides starting salary of NIS 44,000/month, rising to NIS 68,750/month upon milestones.","No family relationships or related-party transactions disclosed per Reg S-K Items 401(d) and 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135526,"accession_number":"0001641172-25-020569","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","5.03"],"status":"ready","headline":"NanoVibronix raises $8M in private placement of Series H convertible preferred and warrants","event_type":"other_material","confidence":"high","bullets":["Initial closing of $8M gross proceeds: 8,889 Series H preferred shares ($1,000 stated value, convertible at $1.01/sh) and warrants for 4,678,363 shares at $2.25/sh.","Second closing of $2.22M (2,222 preferred shares) contingent on customary conditions.","Net proceeds: $5M to redeem Series X preferred stock; remainder for working capital.","Investor gets right to buy up to $44M additional preferred stock over 36 months at 85% of average VWAP.","Company must seek stockholder approval for issuance exceeding 19.99% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135525,"accession_number":"0001641172-25-020209","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoVibronix shareholders approve reverse stock split with 1:2 to 1:50 range","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment approved: ratio of 1-for-2 to 1-for-50, at Board discretion, within one year.","Votes: 550,179 for, 183,224 against, 33,836 abstentions.","Adjournment proposal approved (573,509 for, 166,066 against) but not needed.","Special meeting held July 17, 2025; previously adjourned from July 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135524,"accession_number":"0001641172-25-018809","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NanoVibronix special meeting adjourned due to lack of quorum; reconvened July 17","event_type":"other_material","confidence":"high","bullets":["Special Meeting opened and adjourned without any business due to absence of quorum.","Reconvened virtually on Thursday, July 17, 2025 at 10:00 a.m. Eastern Time.","Record date for voting remains May 16, 2025 unchanged.","Proxy deadline extended to 11:59 p.m. ET on July 16, 2025; previously submitted proxies remain valid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135523,"accession_number":"0001641172-25-018400","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"NanoVibronix corrects typo in Series G preferred stock Floor Price to $1.91","event_type":"other","confidence":"high","bullets":["Corrected definition of Floor Price from $1.02 to $1.91 in Series G Preferred Stock Certificate of Designation.","Certificate of Correction filed with Delaware Secretary of State on July 8, 2025.","All other terms of Series G Preferred Stock remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152521,"accession_number":"0001641172-25-013620","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"NanoVibronix appoints Doron Besser as CEO; Brian Murphy retires but stays on board","event_type":"leadership","confidence":"high","bullets":["Brian Murphy retired as CEO of NanoVibronix effective June 4, 2025, and will remain as a director.","Doron Besser, previously CEO of subsidiary ENvue Medical Holdings, appointed as CEO effective same date.","NanoVibronix completed acquisition of ENvue on February 14, 2025, creating a combined growth platform.","Besser has a medical device background; previously helped lead superDimension, acquired by Covidien for ~$300M.","Board Chairman Christopher Fashek thanked Murphy and expressed confidence in Besser's leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152520,"accession_number":"0001641172-25-011246","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"NanoVibronix raises $10M in public offering of Series G preferred and warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from 400,000 Series G convertible preferred shares at $25/share, each with a warrant to buy 4.9M common shares at $2.04.","Preferred pays 9% cumulative dividend, convertible at $2.04/share, subject to full-ratchet anti-dilution and 4.99%/9.99% beneficial ownership cap.","Use of proceeds: repay $1.3M debenture (Feb 2025) and up to $700k on $2.5M note (Jan 2025); remainder for general corporate purposes.","Amended Series X preferred: increased authorized shares from 57,720 to 62,220 and cut conversion price to match Series G price.","Dawson James Securities acted as sole bookrunner; offering closed May 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}